Schizophrenia-linked genetic variant renders key brain receptor completely unresponsive to both natural and therapeutic compounds
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 23:16 ET (23-Jun-2026 03:16 GMT/UTC)
A rare genetic variant found in families affected by schizophrenia completely abolishes the function of TAAR1, an emerging drug target for psychiatric disorders. The C182F mutation causes a 40% reduction in receptor surface expression and total loss of response to therapeutic compounds in laboratory studies.
A mini-review in Brain Medicine examines the distinct and often opposing roles of AMPKα1 and AMPKα2 isoforms in Alzheimer's disease pathophysiology. The synthesis reveals that these two variants of the cellular energy sensor AMPK may contribute to cognitive decline through separate molecular pathways, potentially explaining decades of contradictory findings about AMPK's role in neurodegeneration.
A research team from the Kunming Institute of Zoology of the Chinese Academy of Sciences has demonstrated for the first time in non-human primates that auditory stimulation at 40-Hz significantly elevates β-amyloid levels in the cerebrospinal fluid (CSF) of aged rhesus monkeys, with this effect persisting for over five weeks.